Vyera Pharmaceuticals: The Founder Who Blocked Generic Rivals

The Daraprim antitrust judgment ordered Vyera Pharmaceuticals’ founder to surrender $64.6 million in profits from a scheme that blocked generic competition and barred him from the pharmaceutical industry for life. The company controlled the tablets rivals needed for testing and the ingredient suppliers they needed for manufacturing. For an insider handling distribution, purchasing or regulatory work, the case shows how ordinary commercial records can expose a deliberate effort to keep a cheaper drug off the market.

The Federal Trade Commission and seven states brought the case. In its January 14, 2022 opinion, the court found that the founder directed the restrictions that protected Daraprim’s monopoly.

Daraprim’s Price Depended on Keeping Generics Out

Vyera, then called Turing Pharmaceuticals, raised Daraprim’s list price to $750 per tablet in August 2015, shortly after buying the drug’s U.S. rights. The court described the price hike as 4,000%. Its founder wanted closed distribution in place by the price increase. The business plan depended on controlling who could buy the product.

Daraprim contains pyrimethamine, used to treat toxoplasmosis, a parasitic infection particularly dangerous to people with weakened immune systems. The court found that patients had no comparable alternative to Daraprim apart from a generic equivalent approved by the Food and Drug Administration. Before generic entry, Daraprim was the only approved pyrimethamine product on the market.

Patients needed treatment, and generic manufacturers needed access to the branded drug before they could offer an approved alternative. Vyera controlled the product needed on both sides of that divide.

What a Generic Manufacturer Needed to Buy

A generic manufacturer needed Daraprim samples for comparison testing and a source of pyrimethamine for its own tablets. Blocking either purchase could interrupt the approval process. Vyera restricted both.

Bioequivalence testing compares a proposed generic with the branded product, called the reference listed drug. The samples had to be unexpired and come from the same manufacturing lot. Manufacturers also had to retain samples, so obtaining a few loose tablets did not solve the problem.

The ingredient supplier presented a different task. The generic manufacturer had to provide the Food and Drug Administration with information about how its active pharmaceutical ingredient was made. It could include that information in its own application or refer to a supplier’s drug master file, which documents the manufacturing process, facilities and controls.

An established supplier with a U.S. drug master file offered a faster path than developing a manufacturing process from scratch. This is why a list of companies capable of making the chemical did not answer the practical question. A generic manufacturer needed a source it could use in an FDA-approved product.

Closed Distribution Reached Beyond the Warehouse

Vyera’s distribution contracts restricted the kinds of customers allowed to buy Daraprim, capped quantities and required approval for exceptions. Its staff then monitored sales to enforce those restrictions. A generic developer could have the money and a willing intermediary and still fail to obtain the samples.

The company’s class-of-trade restrictions required its approval before distributors could sell to a generic manufacturer or its agent. Hospital agreements limited discounted purchases to the hospital’s own use and prohibited resale. Bottle limits added another barrier: larger orders needed Vyera’s approval even when the customer itself was authorized.

The court rejected patient safety as the explanation. Daraprim was an oral tablet that needed no special shipping, handling, storage or administration. It had been sold openly for decades, and the Food and Drug Administration had not required a restricted-distribution safety program. The first generic later launched through open distribution.

Daily and weekly distributor reports let Vyera identify unusual purchases. Staff followed up to find out whether tablets might reach a generic developer. The reports helped Vyera stop generic developers from buying.

Vyera also used distributor contracts to keep Daraprim sales data away from market-research firms. The court found that these provisions were intended to keep generic companies from seeing accurate sales information. They did not impede Cerovene or Fera, whose delays came from the sample and ingredient restrictions.

Five Bottles Bought Back in a Parking Lot

In April 2018, Vyera paid $750,000 to buy back five bottles that had reached a pharmacy on their way to a supplier of samples for generic-drug testing. That was twice what the pharmacy had paid. The distributor delivered the bottles one day, Vyera flagged the transaction that day, and the chief executive repurchased them in a parking lot the next.

Vyera then blocked that pharmacy’s access and sharply reduced the distributors’ approved-customer lists. The purchase order, sales report, account hold and buyback all concerned the same bottles. Together, they showed the restriction moving from a contract into an intercepted delivery.

The distributors had a financial reason to accept limited sales. Vyera paid them either a fixed fee or a share of the list price based on volume sold. Keeping the drug expensive could reward a distributor even while the contract restricted its customers.

Ingredient Contracts That Kept Other Buyers Out

Vyera also blocked access to the most attractive pyrimethamine suppliers. Its contracts with Fukuzyu and RL Fine cut off the ingredient that generic manufacturers needed, and their terms showed what Vyera was buying.

Fukuzyu’s Agreement Did Little to Secure Vyera’s Supply

Fukuzyu, a Japanese manufacturer, already supplied the ingredient for Daraprim and held a U.S. drug master file. Vyera’s parent, Phoenixus, secured an exclusive agreement covering pyrimethamine for human use in the United States.

The agreement did not require Vyera to forecast its needs or Fukuzyu to reserve stock or manufacturing capacity. It did not require Fukuzyu to prioritize Vyera’s orders. It did not even require the supplier to fill an order that it had not accepted.

The comparison with Fukuzyu’s agreement for GSK was telling. That contract required forecasts, production commitments and sufficient manufacturing capacity, without exclusivity. Vyera secured the power to exclude competing buyers while leaving basic supply protections out of its own agreement.

RL Fine Was an Alternative Until Vyera Closed It Off

RL Fine was the next attractive source. It already manufactured pyrimethamine and held a European drug master file, though it had not filed one in the United States. Vyera initially pointed investigators to RL Fine as an alternative available to generics. It then moved to block that alternative after learning that competitors planned to use it.

Vyera paid toward preparing a U.S. drug master file and agreed to royalties on Daraprim sales. Yet the contracts did not require RL Fine to file the document or condition payment on completing the necessary work. RL Fine stopped supplying generic manufacturers, took no steps toward filing the U.S. file, and never became an approved backup source for Daraprim.

The court described what the payments accomplished:

Vyera’s executive responsible for regulatory matters did not even learn about the RL Fine contract until preparing for trial. The person who would have helped qualify a backup supplier had been outside the arrangement.

Generic Manufacturers Left a Record of the Delay

Cerovene’s purchasing history showed the change plainly. Before the restrictions, a pharmacy obtained nine bottles for its testing in about a day. When Cerovene later needed new samples, it spent roughly a year trying to buy them and obtained only three bottles at a cost of $375,000.

The need for new samples followed a supplier change. An import ban imposed by the Food and Drug Administration on Cerovene’s original ingredient supplier forced it to seek another source. Fukuzyu refused supply, so Cerovene turned to RL Fine. The agency required new bioequivalence testing with that ingredient and unexpired Daraprim. Cerovene’s earlier samples had expired.

A bottle obtained through one intermediary could not be combined with three obtained through another because they came from different manufacturing lots. Cerovene asked the agency to reduce the sample requirement. The agency eventually allowed testing with the three matching bottles.

At the same time, RL Fine told Cerovene it would no longer supply more pyrimethamine despite their existing contract. Cerovene searched for another supplier while pursuing testing with the ingredient it had already received. The two restrictions kept meeting inside the same development program.

Fera encountered a similar sample problem. It purchased two bottles for $115,000 each, but held off buying more because the lot might expire before testing. When it returned for more, its supplier reported that Vyera had bought back the inventory. Fera’s requests to the Food and Drug Administration for testing and sample-retention waivers recorded the difficulty as it happened.

Supplier letters, purchase attempts and FDA correspondence connected Vyera’s commercial decisions to the generic companies’ interrupted work. For the excess-profit calculation, the court adopted a conservative estimate that the conduct delayed Cerovene’s entry by eighteen months. That was lost competition patients and purchasers could have had earlier.

Generic Entry Changed the Price and the Buying Decisions

Dr. Reddy’s launched Cerovene’s generic in March 2020. The average net price of all FDA-approved pyrimethamine fell from $228 in 2019 to $166 in 2020, a 27% decline.

Daraprim sales dropped 49% in the nine months after entry compared with the preceding nine months. Vyera’s revenue and gross profits from Daraprim fell 59% between 2019 and 2020. The court could compare the market Vyera had protected with the market after an independent rival arrived.

Pharmacy benefit managers gained an alternative they could favor on their covered-drug lists. Vyera responded with rebates and offers to substitute its brand for a generic, but buyers could now exclude Daraprim and cover cheaper competing products. The blocked samples and ingredient contracts had delayed that buying choice.

The Founder’s Liability Followed His Decisions

The court held the founder personally responsible because he conceived, directed and maintained the scheme. He continued to control business strategy after leaving the chief executive position. As the largest shareholder, he could change management and use that power to keep the restrictions in place.

He argued that he had not signed the contracts. The court traced the instructions and control behind them. For employees who saw decisions arrive from outside the formal management structure, that is a central feature of this case: the signature page did not tell the whole story.

The civil judgment required him to surrender the company’s excess profits from the delayed competition and imposed a lifetime pharmaceutical-industry ban.

In December 2021, Vyera and Phoenixus agreed to provide up to $40 million in relief through a separate settlement that also resolved related class claims.

Can Antitrust Evidence Lead to a Whistleblower Reward?

Our whistleblower experts work out with you whether the conduct you know can support a case that pays a whistleblower reward. Sample requests, supplier contracts and internal instructions can show how a company blocked competition. We connect that commercial evidence to the transactions and government payments that may matter to your case.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

You Know Why the Order Was Blocked

Our whistleblower experts want to understand how supply access or data restrictions kept generic competitors from developing a Daraprim alternative.